Biogen Inc. (NASDAQ: BIIB) Q2 2022 earnings call dated Jul. 20, 2022 Corporate Participants: Michael Hencke -- Head of Investor Relations. Michel Vounatsos -- Chief Executive
Biogen Inc.
-(BIIB)
Get the latest Biogen Inc. (BIIB) stock news, earnings analysis, earnings conference calls, earnings transcripts from AlphaStreet.
Infographic: Key highlights from Biogen (BIIB) Q2 2022 earnings results
Biogen Inc. (NASDAQ: BIIB) reported second quarter 2022 earnings results today. Total revenue decreased 7% year-over-year to $2.58 billion. Net income attributable
Biogen’s (BIIB) long-term prospects look intact despite Alzheimer’s drug setback
Biogen Inc. (NASDAQ: BIIB) is currently going through a difficult phase as the biotechnology firm’s main products face stiff competition and the
Key highlights from Biogen’s (BIIB) Q1 2022 earnings results
Biogen Inc. (NASDAQ: BIIB) reported first quarter 2022 earnings results today. Total revenue decreased 6% year-over-year to $2.53 billion. GAAP net income attributable
Biogen, Inc. (BIIB) Q4 2021 Earnings Call Transcript
Biogen, Inc. (NASDAQ: BIIB) Q4 2021 earnings call dated Feb. 03, 2022 Corporate Participants: Michael Hencke -- Head of Investor Relations Michel Vounatsos -- Chief Executive
BIIB Earnings: Key quarterly highlights from Biogen’s Q4 2021 financial results
Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2021 earnings results today. Total revenue decreased 4% year-over-year to $2.73 billion. GAAP net income
Biogen (BIIB) stock research summary | Q3 2021
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these
Biogen, Inc. (BIIB) Q3 2021 Earnings Call Transcript
Biogen, Inc. (NASDAQ: BIIB) Q3 2021 earnings call dated Oct. 20, 2021 Corporate Participants: Michael Hencke -- Investor Relations Michel Vounatsos -- Chief Executive Officer Alfred
Biogen posts Q3 earnings well above estimates
Biogen (NASDAQ: BIIB) reported third-quarter 2021 financial results before the regular market hours on Wednesday. The company reported Q3 revenue of $2.78
Biogen Inc. (BIIB) Q2 2021 Earnings Call Transcript
Biogen Inc. (NASDAQ: BIIB) Q2 2021 earnings call dated Jul. 22, 2021 Corporate Participants: Mike Hencke -- Director of Investor Relations Michel Vounatsos -- Chief Executive
Biogen (BIIB) Earnings Infographic: Q2 profit, revenue drop but top estimates
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Thursday said its second-quarter earnings and revenues decreased from last year. The results, however, came in
Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development
LLY Stock: Is Eli Lilly a good bet in COVID-challenged healthcare market?
For pharmaceutical companies, 2020 was a busy year when the healthcare sector went into overdrive to deal with the challenges posed by
Biogen Inc. (BIIB) Q1 2021 Earnings Call Transcript
Biogen Inc. (NASDAQ: BIIB) Q1 2021 earnings call dated Apr. 22, 2021 Corporate Participants: Mike Hencke -- Director of Investor Relations Michel Vounatsos -- Chief Executive
Infographic: How Biogen (BIIB) performed in Q1 2021
Biogen Inc. (NASDAQ: BIIB) reported first quarter 2021 earnings results today. Total revenues decreased 24% year-over-year to $2.6 billion. On a constant
Earnings calendar for the week of April 19
The market rally gathered pace this week amid impressive quarterly results, led by the banking sector, and positive economic data. Leading stock
Biogen, Inc. (BIIB) Q4 2020 Earnings Call
Biogen, Inc. (NASDAQ: BIIB) Q4 2020 earnings call dated Feb. 03, 2021 Corporate Participants: Mike Hencke — Director, Investor Relations Michel Vounatsos — Chief Executive Officer Alfred
Biogen, Inc. (BIIB) Q4 2020 Earnings Call Transcript
Biogen, Inc. (NASDAQ: BIIB) Q4 2020 earnings call dated Feb. 03, 2021 Corporate Participants: Mike Hencke -- Director, Investor Relations Michel Vounatsos -- Chief Executive Officer
Infographic: Key financials of Biogen (BIIB) Q4 2020 earnings report
Biogen (NASDAQ: BIIB) reported fourth-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 22% decline in
Earnings calendar for the week of January 11
Stock markets responded positively to the latest developments in presidential election. On the heels of the Dow Jones Industrial Average achieving a
Biogen (BIIB) might need to revisit pipeline after Alzheimer’s drug setback
The controversy surrounding biotechnology firm Biogen's (NASDAQ: BIIB) Alzheimer's drug Aducanumab took a positive turn last week after the FDA issued a